CIBMTR Reporting Implementation Guide
0.1.11 - Trial Use 1

This page is part of the CIBMTR Reporting Implementation Guide (v0.1.11: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 Home
... 2 Access Credentials
... 3 Appendices
... 4 Bundles
... 5 Connection Guide R 4
... 6 CRID Assignment FHIR
... 7 CRID Assignment Non FHIR
... 8 Cytogenetics
... 9 Direct FHIR STU 3
... 10 Endpoints
... 11 Example Code
... 12 Form 2450
... 13 Laboratory Observations
... 14 Medications
... 15 Patient
... 16 Vital Signs
... 17 Artifacts Summary
.... 17.1 CIBMTR Additional Drugs in Peri-Transplant Period
.... 17.2 CIBMTR Cytogenetics Profile
.... 17.3 CIBMTR GVHD Prophylaxis Medication
.... 17.4 CIBMTR Medication (us-core)
.... 17.5 CIBMTR Medication Administration (mcode)
.... 17.6 CIBMTR Medication Related (mcode)
.... 17.7 CIBMTR Medication Request (mcode)
.... 17.8 CIBMTR Mobilizing Agents Medication
.... 17.9 CIBMTR Observation Laboratory Results Profile (us-core)
.... 17.10 CIBMTR Observation Laboratory Results: Priority Variables
.... 17.11 CIBMTR Patient Profile (us-core)
.... 17.12 CIBMTR Planned Post-HCT Disease Therapy Medication
.... 17.13 CIBMTR Prep Regimen Medication
.... 17.14 CIBMTR Prior Exposure Medication
.... 17.15 CIBMTR Vital Signs Results Profile (US Core)
.... 17.16 CIBMTR Vital Signs-Height Profile (us-core)
.... 17.17 CIBMTR Vital Signs-Weight Profile (us-core)
.... 17.18 CIBMTR Ancestry Extension
.... 17.19 Auto Differential panel - Blood (57023-4)
.... 17.20 CBC panel - Blood by Automated count (58410-2)
.... 17.21 CBC W Auto Differential panel - Blood (57021-8)
.... 17.22 CBC W Differential panel, method unspecified - Blood (69742-5)
.... 17.23 CBC W Ordered Manual Differential panel - Blood (57782-5)
.... 17.24 CIBMTR Ancestry ValueSet
.... 17.25 CIBMTR Patient Ancestry Value Set
.... 17.26 CIBMTR Priority Variables Value Set (FY21)
.... 17.27 CIBMTR Priority Variables Value Set (FY22)
.... 17.28 CIBMTR Priority Variables Value Set for Epic App (FY21)
.... 17.29 CIBMTR Vital Signs Concept Set
.... 17.30 CIBMTR Vital Signs Value Set
.... 17.31 Differential panel, method unspecified - Blood (69738-3)
.... 17.32 Disorders of hematopoietic structure
.... 17.33 Erythrocyte morphology panel - Blood (58408-6)
.... 17.34 GVHD ICD-10 Codes
.... 17.35 GVHD SNOMED CT Codes
.... 17.36 GVHD Type Value Set
.... 17.37 Leukocyte morphology panel - Blood (58407-8)
.... 17.38 Manual Differential panel - Blood (24318-8)
.... 17.39 Platelet morphology panel - Blood (58406-0)
.... 17.40 Presence Answer List
.... 17.41 RxNorm - Additional Drugs in Peri-Transplant Period
.... 17.42 RxNorm - Alemtuzumab
.... 17.43 RxNorm - All of Form 2400
.... 17.44 RxNorm - Anti-Thymocyte Globulin
.... 17.45 RxNorm - Bortezomib
.... 17.46 RxNorm - Busulfan
.... 17.47 RxNorm - Carmustine
.... 17.48 RxNorm - Cyclophosphamide
.... 17.49 RxNorm - Cytarabine
.... 17.50 RxNorm - Defibrotide
.... 17.51 RxNorm - Etoposide
.... 17.52 RxNorm - Fludarabine
.... 17.53 RxNorm - GVHD Prophylaxis
.... 17.54 RxNorm - Melphalan
.... 17.55 RxNorm - Mobilizing Agents (auto only)
.... 17.56 RxNorm - Post-HCT Disease Therapy Planned
.... 17.57 RxNorm - Prep Regimen
.... 17.58 RxNorm - Prior Exposure: Potential Study Eligibility
.... 17.59 RxNorm - Rituximab
.... 17.60 RxNorm - Thiotepa
.... 17.61 RxNorm - Treosulfan
.... 17.62 RxNorm - Ursodiol
.... 17.63 Smear morphology panel - Blood (34994-4)
.... 17.64 SNOMED Myelodysplastic Diseases
.... 17.65 CIBMTR Ancestry CodeSystem
.... 17.66 ABOBloodGroupObservationLOINC
.... 17.67 ABOBloodGroupObservationSNOMED
.... 17.68 ABORhObservationLOINC
.... 17.69 ABORhObservationSNOMED
.... 17.70 AlbuminObservation
.... 17.71 BasophilsObservation
.... 17.72 BodyHeight
.... 17.73 BodyWeight
.... 17.74 CMVDNAViralLoadCopiesmL
.... 17.75 CMVDNAViralLoadIUmL
.... 17.76 CMVIgAbPresenceSNOMED
.... 17.77 CMVIgGAbPresenceLOINC
.... 17.78 CMVIgMAbPresenceLOINC
.... 17.79 CMVIgMAbPresenceSNOMED
.... 17.80 Cytogenetics-Example-1
.... 17.81 EosinophilsObservation
.... 17.82 HemoglobinObservation
.... 17.83 LeukocytesObservation
.... 17.84 Medication-Cyclophosphamide-Example
.... 17.85 Medication-Etoposide-Example
.... 17.86 Medication-GVHD-Prophylaxis-Example
.... 17.87 Medication-Mobilizing-Agent-Example
.... 17.88 Medication-Peri-Transplant-Example
.... 17.89 Medication-Post-HCT-Disease-Therapy-Example
.... 17.90 Medication-Prep-Regimen-Example
.... 17.91 Medication-PriorExposure-Example
.... 17.92 MedicationAdministration-Example1
.... 17.93 MedicationAdministration-Example2
.... 17.94 MedicationRequest-Etoposide-Example
.... 17.95 MetamyelocytesObservation
.... 17.96 NeutrophilsObservation
.... 17.97 PatientExample1
.... 17.98 PatientExample2
.... 17.99 PatientExample3
.... 17.100 PatientExample4
.... 17.101 PatientExample5
.... 17.102 PatientExample6